Dean Tang

18PUBLICATIONS
84CO-AUTHORS
Molecular targetsCancer cell biologyPredictive and prognostic markersInfant and child healthCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 28, 2026
Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.

|Jun 04, 2026
A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer.

|May 01, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.

|Mar 26, 2026
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma.

Jiao Zhang, Winnie Ong, Alexandra Rasnitsyn

|Jul 17, 2025
Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes.

Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou

|Jul 08, 2025
Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62.

Daric J Wible, Wen Jess Li, Xiaozhuo Liu

Pageof 3

Frequent Collaborators

7 joint publications

Xiaozhuo Liu

3 joint publications

Wen Jess Li

2 joint publications

Daric J Wible

2 joint publications

Shawn B Bratton